Deal facts
- Buyer
- XOMA Royalty Corporation
- Target
- Generation Bio Co.
- Deal value
- Not disclosed
- Announced
- 15 December 2025
- Status
- Completed
- Sector
- Healthcare
- Country
- United States
- Consideration
- cash, earn-out
Sources
More M&A Tools
Explore the Toolkit
Tools, frameworks and AI assistants designed for entrepreneurs serious about M&A.
Access nowDeal timeline
2 updates- CompletedClosed
XOMA Royalty Corporation completes acquisition of Generation Bio Co.
Item 2.01 Completion of Acquisition or Disposition of Assets. As previously disclosed, XOMA Royalty Corporation (“ XOMA Royalty ”) entered into an Agreement and Plan of Merger, dated December 15, 2025 (the “ Merger Agreement ”), with Generation Bio Co., a Delaware corporation (the “ Company ” or “ Generation Bio ”), and XRA 7 Corp., a Delaware corporation and a wholly owned subsidiary of XOMA Roya
Source - CompletedClosed
XOMA Royalty Corporation completes acquisition of Generation Bio Co.
Item 1.01 Entry into a Material Definitive Agreement. As previously reported, on August 2, 2018, Generation Bio Co. (the “Company”) entered into a lease agreement (as subsequently amended, the “Lease”) with BMR-Rogers Street LLC (the “Landlord”), pursuant to which the Company leased approximately 71,562 square feet of research and development, laboratory and office space at 301 Binney Street, Camb
Source
Explore
Browse adjacent archives
Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.
Similar deals
Similar deals
Other Healthcare M&A activity tracked by Exit Mode.
Trafalgar Asset Management, LLC to acquire The Greater Cannabis Company, Inc.
Trafalgar Asset Management, LLC has agreed to acquire The Greater Cannabis Company, Inc. in a going private transaction. The deal was announced on 6 July 2026, following…
- Buyer
- Trafalgar Asset Management, LLC
- Target
- The Greater Cannabis Company, Inc.
- Deal value
- Not disclosed
- Deal type
- going private
Hanmi Pharmaceuticals Co. Ltd. to acquire Aptose Biosciences Inc.
Hanmi Pharmaceuticals Co. Ltd. has agreed to acquire Aptose Biosciences Inc. in a going private transaction valued at USD 3,466,470. The consideration for this deal cons…
- Buyer
- Hanmi Pharmaceuticals Co. Ltd.
- Target
- Aptose Biosciences Inc.
- Deal value
- USD 3,466,470
- Deal type
- going private
GlaxoSmithKline LLC to acquire Nuvalent, Inc.
GlaxoSmithKline LLC has agreed to acquire Nuvalent, Inc. in a going private transaction. The deal was announced on 9 June 2026 and completed on 15 July 2026. The conside…
- Buyer
- GlaxoSmithKline LLC
- Target
- Nuvalent, Inc.
- Deal value
- Not disclosed
- Deal type
- going private
FONAR, LLC to acquire FONAR Corporation
FONAR, LLC has agreed to acquire FONAR Corporation in a going private transaction completed on 3 June 2026. The deal involves the purchase of the US-based healthcare com…
- Buyer
- FONAR, LLC
- Target
- FONAR Corporation
- Deal value
- Not disclosed
- Deal type
- going private
Zydus Worldwide DMCC to acquire Assertio Holdings, Inc.
Zydus Worldwide DMCC has agreed to acquire Assertio Holdings, Inc. in a going private transaction valued at an undisclosed amount. The deal, announced on 13 May 2026, wa…
- Buyer
- Zydus Worldwide DMCC
- Target
- Assertio Holdings, Inc.
- Deal value
- Not disclosed
- Deal type
- going private
Buyer history
XOMA Royalty Corporation
See every published Exit Mode archive entry where this buyer appears.
View buyer profileMethodology
How this page is built
Layer 1 facts come from source documents, Layer 2 turns those facts into a readable narrative, and Layer 3 only appears where the editorial team flags a founder-relevant deal.
Back to the archive